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Introduction
Malignant pleural mesothelioma (MPM) is a cancer 
mainly caused by asbestos exposure and with a long latency 
between asbestos exposure and tumor diagnosis. However, 
according to the reports reviewed by Gibbs and Berry (1), 
only a minority of exposed people develops MPM. In fact, 
the incidence among professionally exposed workers was 
shown to vary between 0.5% and 18.0%. Although this 
risk could be modulated by the type of asbestos handled 
by workers and by the protective measurements to lower 
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their individual exposure, various hints suggested that 
other important cofactors could play a role, in particular 
the genetic susceptibility. In fact, even a lifetime-risk 
of 18% following asbestos exposure does not explain, 
satisfactory, the observation of families with multiple cases. 
Furthermore, most of them show MPM among relatives 
without an ascertained exposure to asbestos. In this context, 
even more impressive is the case of Cappadocians families 
exposed to erionite. Moreover, genetic studies highlighted 
the presence of low-risk susceptibility alleles as well as 
other more penetrant inherited mutations. This review will 
explore the latest concepts of the genetic susceptibility 
to MPM.
Familial clustering of MPM
The hypothesis that genetics may be involved derives 
from the frequent reports (at least 20 so far) of MPM 
cases recurring in the same family. In 1980, Risberg et al. 
highlighted the heredity as a key element in determining 
MPM development. They described a familial clustering 
in which three brothers, one sister and their father died of 
MPM. All of them smoked, and 4 of the 5 cases have been 
probably occupationally exposed to asbestos (2). 
The occurrence of MPM among relatives was reported 
also by Bianchi et al. (3). Forty MPM out of 610 analyzed 
were familial cases, all previously exposed to asbestos. The 
fact that genetic factors could be crucial for these patients 
had been suggested by the existence of blood relationships 
among their members in 15 different families.
In 2013, Kalogeraki et al. studied a single family in which 
MPM occurred in the father and daughter. Both of them 
developed this neoplasm characterized by similar clinic 
features. The father has been affected at the age of 42 years 
and the daughter at the age of 35 [14 years later (4)].
On the other hand, Ascoli et al. analyzed the features 
of MPM in blood relatives that could explain the disease 
clustering, recruiting 11 clusters (22 cases) identified 
among 1,954 Italian MPM cases, and 51 clusters (120 
cases) extracted from 33 studies. The authors found MPM 
profiles similar in both consanguineous and unrelated 
patients and that the majority of clusters were linked to 
asbestos exposure, thus suggesting that a low proportion 
of familial cases is not influenced by a large genetic 
component (5). Moreover, de Klerk et al. suggested that the 
genetic component plays a role important but not weighty 
in mesothelioma, similar to what observed in other types 
of neoplasm. Indeed, they explored the history of 11,000 
asbestos workers from the cancer and death registries of 
Wittenoom (Australia), and found 369 families with at 
least one case of mesothelioma and a further 25 cases of 
mesothelioma among relatives in the same families, with 
12.9 predicted cases (6).
In summary, when a blood relationship exists between 
MPM cases, the presence of susceptibility factors 
interacting with asbestos exposure could be suggested. 
However, a strong confounder for a genetic study refer 
to indirect risk for relatives of asbestos workers, who can 
inhale fibers through daily behaviors such as washing 
contaminated working clothes, or even hugging the father 
with contaminated working clothes. Vianna and Polan 
recruited 52 women and matched controls and analyzed the 
risk to develop MPM when exposed to asbestos in indirect 
way (7). The authors observed that the risk was significantly 
increased when woman live with husbands or other persons 
working in asbestos-related industries. These evidences 
suggest that the shared asbestos exposure could be the 
main factor of MPM affecting different components (not 
genetically related) within the same family. This result has 
been reported also by Anderson et al. and other authors (8,9).
Is a cancer in a first-degree relative (FDR) a risk 
factor for MPM?
Heineman et al. performed telephone interviews to 196 
MPM patients and controls and reported histories of cancer 
in FDRs (10). They highlighted a strong risk to develop 
mesothelioma for patients (exposed to asbestos) having 
cancer in two or more FDRs. Moreover, even if in a not 
statistically significant way, they noticed that the asbestos-
related risk to develop MPM was higher among men with a 
reported family history of cancer compared to men without 
a positive familial history.
In 1998 Ascoli et al. identified a cluster of MPM in one 
cousin and three sisters (11). All of them were professionally 
exposed to asbestos. The authors hypothesized that 
inherited factors could play a role. Indeed, through a deep 
analysis of the pedigree, they noticed the presence of 
malignant-cancers in first-degree (pleura and lung, mother, 
and larynx, brother), second-degree (lung, aunt and uncle) 
and third-degree (lung, cousin) relatives.
Ohar et al. distinguished mesothelioma patients from 
others exposed to asbestos (12), and they found that subjects 
with mesothelioma were younger at first asbestos exposure, 
had a higher prevalence of a previous cancer diagnosis, and 
had a greater risk of cancer among FDRs (point estimate for 
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risk, 2.93; 95% CI, 2.50–3.50), considering other asbestos-
exposed groups as reference.
These evidences are intriguing, but not strong enough, 
to confirm that a positive familial history of cancer could 
be a risk factor for mesothelioma, or could indicate an 
increased susceptibility to mesothelioma in association with 
asbestos exposure.
MPM cases in Cappadocia villages: an epidemic?
In three villages of Cappadocia (Tuzkoy, Karain, and 
‘‘Old’’ Sarihidir), a study on “epidemic” of MPM was 
conducted given that about half of the occupant died for this 
malignancy. The erionite, a mineral of the zeolite family 
employed as building material, was considered as the unique 
etiologic factor. It has been supposed that inhalation of even 
low levels of erionite was sufficient to cause mesothelioma. 
Indeed, a study on rats showed that inhalation of erionite 
or its intraperitoneal inoculation caused mesothelioma in 
27 out of 28 rats, and 40 out of 40, respectively, whereas 
other types of asbestos induced mesotheliomas at a lesser 
extent (19 out of 40, and 1 out of 28, respectively) (13). In 
2001, Roushdy-Hammady and collaborators analyzed the 
pedigree of some families until the sixth generation (for 
a total of 526 individuals) to understand whether MPM 
could be genetically transmitted (14): in six families MPM 
showed obvious familial clustering in which 87 children 
were identified with at least one affected parent. Of these 
87 children, 41 developed MPM as adults (on average 50% 
of offspring develops MPM when at least one parent is 
affected). Interestingly, they reported that MPM occurred 
mostly in certain families than in others. From these 
observations, they postulated that in Cappadocia villages, 
genetic predisposition and environmental erionite exposure 
would increase the risk of MPM with a synergistic effect. 
This finding was further corroborated by Dogan et al. (15), 
and Carbone and collaborators (16) who initially hypothesized 
that a unique and more carcinogenic erionite was present 
in certain houses and caused MPM just there. After the 
X-ray diffraction pattern analysis, they found the same 
type of erionite in all three Cappadocian villages, with or 
without a malignant mesothelioma epidemic, in households 
with high or no incidence of MPM. When high-risk 
malignant mesothelioma family members married into 
families at low risk, mesothelioma appeared in the progeny. 
On the other hand, genetically predisposed family members 
born and raised outside the malignant mesothelioma villages 
did not seem to develop this neoplasm. These results led 
the authors to postulate that epidemic of mesothelioma 
is caused by erionite exposure in a population carrying a 
putative predisposing gene.
Metintas et al. studied a group of 162 immigrants coming 
from the village Karain and living in Sweden for many 
years (17). They recorded several data, as asbestos exposure, 
time residing in the Turkey village, and clinical features 
as pathological diagnosis. During the time of observation, 
18 of the immigrants died, and 14 of them for MPM. 
Moreover, other five patients, still alive, were diagnosed 
with mesothelioma.
Thus, incidence rates remained similar to that of the two 
Turkish villages and very high with respect with Swedish 
rates. The risk increased with duration of residence: no cases 
were observed in subjects living in Karain less than 10 years. 
All these findings suggest that malignant mesothelioma 
is not directly related to duration of erionite exposure, 
but (perhaps) a short exposure to erionite is needed for 
triggering the disease in susceptible people. Unfortunately, 
no results for a “Cappadocia” gene of susceptibility to 
MPM under erionite exposure have been obtained, yet.
Germline mutations and MPM
Testa et al. searched for specific genetic predisposing 
factors (18), and discovered two families with a high 
incidence of mesothelioma and characterized by germline 
mutations in BRCA1-associated protein 1 (BAP1), causing 
the biallelic inactivation of the gene. Six members of the 
first analyzed family, all affected by MPM presented the 
same mutation, whereas unaffected family members did 
not. In the second analyzed family, three individuals with 
MPM were characterized by a C>T change within exon 
16, encoding for a stop codon. Moreover, the authors have 
identified that in addition to MPM, some BAP1 mutation 
carriers developed uveal melanoma.
Two of 26 sporadic mesotheliomas patients were found 
to present germline BAP1 mutations, and interestingly, both 
of them were previously diagnosed with uveal melanoma. 
It has been shown that aberrant BAP1 expression and 
truncating mutations could be present also in sporadic 
mesotheliomas without germline mutations. From these 
findings, a BAP1-related cancer syndrome characterized 
by mesothelioma and uveal melanoma has emerged. Up to 
now, BAP1 is the only gene known to confer an increased 
susceptibility to MPM. BAP1 has several cell-intrinsic 
tumor suppressive functions, such as regulation of cell cycle 
and replication, gene transcription, DNA damage response, 
S249Journal of Thoracic Disease, Vol 10, Suppl 2 January 2018
© Journal of Thoracic Disease. All rights reserved.   J Thorac Dis 2018;10(Suppl 2):S246-S252jtd.amegroups.com
as well as a modulation in the inflammatory response to 
crocidolite. For this reason, subsequent studies succeeded in 
the years to ascertain the role of this gene in MPM.
Xu et al. investigated the reason for which mesothelioma 
appears in some BAP1 families and not in others, and 
whether asbestos exposure is a requirement for mesothelioma 
development in BAP1 mutation carriers (19). For this reason, 
they generated a BAP1 knockout mouse model, verified its 
susceptibility to mesothelioma following chronic exposure to 
asbestos and showed that these mice presented a significantly 
higher incidence of asbestos-induced mesothelioma than 
wild-type (WT) littermates (73% vs. 32%, respectively).
In a further in vivo study, Napolitano et al. demonstrated 
that mice heterozygotes for mutation within BAP1 and 
exposed to asbestos fibers at minimal doses showed changes 
in the inflammation circuitry such as increased levels of 
inflammatory macrophages, and reduced levels of specific 
chemokines and cytokines, compared to their wild type 
littermates (20). Moreover, heterozygotes mice showed 
high rates of mesothelioma induced with minimal amount 
of asbestos fibers that could not induce mesothelioma in 
wild type mice. These results suggest that low doses of 
fibers increase the risk to develop the disease in genetically 
predisposed subjects carrying inherited mutations within 
BAP1 and this could occur following to changes of the 
peritoneal inflammatory circuitry.
Thus, it has agreed that germline BAP1 mutations are 
associated with a novel cancer syndrome characterized by 
uveal melanoma, cutaneous melanoma, melanocytic tumors, 
and other cancers like breast/ovary (21). 
Several studies have investigated BAP1 mutation 
in relation to sporadic MPM. Betti et al. described the 
mutational status of BAP1 in five families with multiple 
MPM patients and in 103 sporadic cases (22). A familial 
proband carried an inherited mutation causing a truncated 
BAP1 protein. The authors noticed that MPM developed in 
three subjects previously exposed to asbestos who carried the 
same mutation of the proband within that family, whereas 
a different type of tumor was observed in another carrier 
never exposed to asbestos (a muco-epidermoid carcinoma). 
All the other analyzed families and subjects did not show 
any mutation within BAP1. In summary, inherited mutations 
within BAP1 are rare among sporadic MPM patients. Similar 
results have been found also by Rusch et al. [78 sporadic 
MPM analyzed and 1 germline Ser342Ser within BAP1 
identified, minor allele frequency (MAF) =0.2%] (23), 
and by Sneddon et al. (115 sporadic MPM analyzed and 0 
germline variants within BAP1 found) (24).
In addition to BAP1, mutations in neurofibromin 2 (NF2) 
have also been associated with the development of MPM. 
NF2 maps to 22q12.2, a region frequently rearranged in 
MPM (25-27). This is a tumor suppressor gene, mutated 
in the type 2 neurofibromatosis (an autosomal dominant 
hereditary disease characterized by tumors of the nervous 
system). It has been shown that half of MPM cases present 
mutations within NF2 gene (28,29). Although NF2 disease 
is not usually associated with MPM (30), NF2 patients show 
increased risk to develop MPM when exposed to asbestos (31), 
likely because of a potential link between asbestos exposure 
and the NF2 inactivation (32). The loss of NF2 function has 
been proposed to be an early event in the MPM (33).
Genetic polymorphisms and MPM
Several studies suggested that common polymorphisms within 
genes involved in the metabolism of xenobiotics or within 
the DNA repair systems could constitute a risk factor for the 
disease. Actually, there are studies reporting an association 
between MPM and polymorphisms within GSTM1, NAT2, 
or manganese superoxide dismutase (MnSOD). GSTM1 
belongs to the “glutathione S-transferase” gene family and 
allows the conjugation of glutathione with electrophilic 
substances, such as reactive oxygen species (ROS). It has 
been reported that the lack of the locus is associated with 
the risk of MPM (34,35). Increased risks were also reported 
for subjects with the null genotype for GSTM1 gene, and 
slow acetylators for NAT2 (36). The NAT2 gene encodes 
the N-acetyltransferase, and other studies report that 
polymorphisms within this gene possibly are involved in the 
etiology of the MPM (37). The oxidative stress induced by 
asbestos fibers could be scavenged also by MnSOD (38). 
Although no activity of this enzyme is measurable in normal 
mesothelial cells, it is dramatically increased in MPM cells (39). 
The polymorphism Alanine-to-Valine at codon 16 within 
MnSOD is predicted to affect the protein secondary structure 
and it could cause an impairment in the transport of the 
enzyme to the mitochondria (40). Ninety cases of MPM and 
395 controls were analyzed and the Ala/Ala genotype was 
associated with the risk of MPM (35). Among the genes 
of the DNA repair systems, associations with MPM were 
described for XRCC3, a protein involved in repairing DNA 
breaks through the homologous recombination. In a case-
control study carried out in the Casale Monferrato area, 
variants of this gene were actually associated with increased 
risks (41). Moreover, associations between MPM and 
XRCC3-241T or XRCC1-399Q variants were found in a 
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different study focused on a larger area of the Piedmont (42). 
In a recent study by Betti et al., ten germline and pathogenic 
truncating variants (PTVs) were identified within PALB2, 
BRCA1, FANCI, ATM, SLX4, BRCA2, FANCC, FANCF, 
PMS1 and XPC. Interestingly, all these genes are involved 
in DNA repair pathways and are identified in almost 10% 
of the analyzed MPM patients, suggesting that they did not 
efficiently repair the DNA damages induced by asbestos (43). 
Genome-wide association studies (GWAS) have provided 
significant progress in the field of cancer genetics. Two 
GWAS on MPM were performed so far. In both of them, 
no single nucleotide polymorphisms (SNPs) achieved 
formal genome-wide statistical significance, likely because 
of the limited number of patients enrolled. One study was 
performed by Cadby et al., on 428 MPM cases and 1,269 
controls from Western Australia (44). The other on 407 
MPM cases and 389 controls from Italy, was performed by 
Matullo and collaborators (45). From the Australian study, 
suggestive results for MPM risk were identified within 
SDK1, CRTAM and RASGRF2 genes, and within the 2p12 
chromosomal region. These genes are important in cell 
adhesion and/or cell migration and they could have a role 
in the cellular response to asbestos fibers. Matullo’s study 
revealed associations within risk of MPM and SNPs within 
specific loci often somatically rearranged in MPM. This 
is the case of SNPs within SLC7A14, THRB, CEBP350, 
ADAMTS2, ETV1, PVT1, MMP14 and chromosomal 
regions 3q26.2, 4q32.1, 14q11.2, 15q14 and 7p22.2 
associated with a 2–3-fold increased risk. The region 7p22.2 
includes the SDK1 gene region, detected also in the Australian 
study (44). SDK1 encodes for an adhesion molecule. Cellular 
stress, e.g., by ROS, could cause an up-regulation of SDK1, 
such as it occurs in the secretome of starved cancer cells. 
Interestingly, the administration of this secretome to cell 
cultures stimulates the clonogenic capacities of various cell 
lines, and the proliferation and migration of human umbilical 
vein endothelial cells.
In summary, these studies do not shed a definitive 
light on the mechanisms of susceptibility to MPM. This 
is coming from the fact that the neoplasm is rare and it 
is difficult to carry out large case-control studies with an 
adequate sample size allowing the optimal statistical power.
Conclusions
From these findings, it seems that, following asbestos 
exposure, genetic susceptibility could play a mild role in 
affecting the risk to develop sporadic MPM, similarly as 
it occurs for other human cancers. On the contrary, the 
risk of MPM can be affected greatly by inherited germline 
mutations within BAP1 in a context of a multi-cancer 
syndrome. More studies are needed in order to evaluate the 
role of genetics among Cappadocians. 
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